AcuCort (ACUC.ST) Stock Analysis & AI Equity Report
AcuCort (ACUC.ST) overview
AcuCort (ACUC.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, AcuCort reported revenue of SEK 0.7m and operating profit of SEK -26.5m; the year-end share price was 0.60 SEK and market capitalisation was SEK 71.4m. AcuCort is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AcuCort's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About AcuCort
AcuCort AB is a Swedish pharmaceutical company that develops and commercializes Zeqmelit, a fast-dissolving oral film containing dexamethasone. The product is designed for situations where simple administration is important and is approved in Sweden, Denmark, Norway and Finland for uses including acute allergic reactions, croup in children, chemotherapy-related nausea and vomiting, and respiratory support in COVID-19.
Generate the AcuCort report
AcuCort is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AcuCort and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on AcuCort
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.